



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|---|-------------------------------|
| Summary for ARTG Entry: | 95544 | BLACKMORES TRAVEL CALM GINGER |
| ARTG entry for | Medicine Listed | |
| Sponsor | Blackmores Ltd | |
| Postal Address | PO Box 1725, WARRIEWOOD, NSW, 2102 Australia | |
| ARTG Start Date | 10/07/2003 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . BLACKMORES TRAVEL CALM GINGER

| | | | |
|---------------------|-------------------------|-----------------------|------------|
| Product Type | Single Medicine Product | Effective Date | 20/10/2020 |
|---------------------|-------------------------|-----------------------|------------|

Permitted Indications

Traditionally used in Western herbal medicine to decrease/reduce/relieve flatulence/carminative
Traditionally used in Western herbal medicine to relieve digestive discomfort
Traditionally used in Western herbal medicine to decrease/reduce/relieve nausea
Decrease/reduce/relieve symptoms of motion/travel/sea sickness

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size/Poison information

| | |
|------------------|------------------------|
| Pack Size | Poison Schedule |
|------------------|------------------------|

Components

1 . Formulation 1

| | |
|--------------------------------|------------------|
| Dosage Form | Tablet, uncoated |
| Route of Administration | Oral |

Visual Identification

Active Ingredients

| | |
|--|---------------|
| Zingiber officinale root Powder | 400 mg |
|--|---------------|



Australian Government

Department of Health
Therapeutic Goods Administration

Other Ingredients (Excipients)

croscarmellose sodium
hydrogenated vegetable oil
hypromellose
magnesium stearate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary